Home » FDA Clears nContact’s Cardiac Ablation Device

FDA Clears nContact’s Cardiac Ablation Device

January 23, 2013

nContact announced that the FDA has cleared the company’s modifications to its VisiTrax cardiac ablation device, EPi-Sense, now with embedded sensing capability.
BusinessWire

10Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
08Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

FDA Clears nContact’s Cardiac Ablation Device

Upcoming Events

Gene & Cell Therapy Regulation: Comparability and Other New Developments

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

Hyris T-Cell Test Gains CE-IVD Mark

FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

The Revised ICH E8: A Guide to New Clinical Trial Requirements